Table 1 Clinical characteristics of patients with III–IV stage NSCLC

Age (y, mean ± SD)

67.85 ± 9.76

70.96 ± 10.27

74.49 ± 11.41

0.062

Sex

0.320

 Male

91 (87.50%)

59

32

 Female

13 (12.50%)

6

7

Smoking status

0.839

 Smoker

56 (53.85%)

34

22

 Non-smoker

48 (46.15%)

31

17

ECOG PS score

0.015

 0–1

79 (75.96%)

55

24

  > 1

25 (24.04%)

10

15

Pathology

1

 Squamous

36 (34.62%)

23

13

 Non-squamous

68 (65.38%)

42

26

Disease stage

0.089

 III

21 (20.20%)

17

4

 IV

83 (79.80%)

48

35

Covid-19 vaccination

0.005

 Yes

25 (24.04%)

22

3

 No

79 (75.96%)

43

36

Vaccination doses

–

 0

79 (75.96%)

43

36

 1

4 (3.85%)

4

0

 2

13 (12.50%)

10

3

 3

8 (7.69%)

8

0

Vaccine type

–

 No

79 (75.96%)

43

36

 CanSino

1 (0.96%)

1

0

 Sinovac–CoronaVac

13 (12.50%)

1

12

 Sinopharm BBIBP-CorV

11 (10.58%)

9

2

History of COVID-19 infection

–

 Yes

0

0

0

 No

104 (100%)

65

39

Treatment line

0.094

 First line

55 (52.89%)

39

16

 Subsequent lines

49 (47.11%)

26

23

Combined therapy

0.280

 Yes

89 (85.58%)

58

31

 No

15 (14.42%)

7

8

Anti-PD-(L)1 treatment

–

 Camrelizumab

14 (13.46%)

9

5

 Pembrolizumab

29 (27.88%)

19

11

Teripulimab

2 (1.92%)

2

0

 Sintilimab

53 (50.96%)

32

21

 Tislelizumab

5 (4.81%)

3

2

 Durvalumab

1 (0.96%)

1

0

Treatment efficacy

-

 Complete remission (CR)

0 (0%)

0

–

 Partial remission (PR)

16 (15.38%)

16

–

 Stable disease (SD)

49 (47.12%)

49

–

 Progression disease (PD)

39 (37.50%)

–

39